Pricing Log in Create free account

BioAtla, Inc. (BCAB) vs Silexion Therapeutics Corp (SLXN)

BioAtla, Inc. and Silexion Therapeutics Corp are both Biotechnology companies. BioAtla, Inc. and Silexion Therapeutics Corp are of similar size ($2.9M and $2.7M). Silexion Therapeutics Corp has the higher net margin (0.00% vs −177.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, BioAtla, Inc. leads on 5 and Silexion Therapeutics Corp on 5.

Valuation

Metric BCAB SLXN Biotechnology median
P/E n/m n/m 8.50
P/S 0.13 n/m 9.71
P/B n/m 2.34 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.04 0.64
EV/Sales 0.63 n/m 9.21
Earnings yield (1,871.32%) (14,489.87%) (33.15%)
Free cash flow yield (1,044.09%) (12,070.84%) (25.50%)

Profitability

Metric BCAB SLXN Biotechnology median
Gross margin 95.44% — 65.16%
Operating margin (180.99%) 0.00% 0.00%
Net margin (177.21%) 0.00% 0.00%
Free cash flow margin (132.29%) 0.00% 0.00%
Return on equity 118.74% (17,021.95%) (56.36%)
Return on assets (171.72%) (277.96%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAB SLXN Biotechnology median
Revenue growth (TTM) 574.65% — 6.02%
EPS growth (last fiscal year) 29.86% 97.73% 30.26%
Revenue growth, 5-year CAGR (28.40%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCAB SLXN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.20 0.94 4.72
Net debt to EBITDA 0.12 0.38 0.96

Dividend

Metric BCAB SLXN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BCAB SLXN Biotechnology median
Market cap 2.89m 2.73m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack